Clinical Research Informer

FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag

pharmaphorum

JANUARY 5, 2022

The c-Met protein thought to be both a driver of cancer itself, as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR inhibitors. The post FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag appeared first on.

Antibody

Antibody Drugs Protein Gene

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

pharmaphorum

DECEMBER 23, 2021

Patritumab deruxtecan achieved an overall response rate of 25% when given as a therapy to patients with EGFR-mutated NSCLC whose cancer had progressed despite treatment with a third-generation EGFR inhibitor like AstraZeneca’s Tagrisso (osimertinib) and platinum-based chemotherapy.

Drugs

Drugs Antibody Clinical Trials Clinical Trials

FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

Stay Connected